Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 2, 2005, Pages 159-163

  Yukawa, E ^a   Suematsu, F ^b   Yukawa, M ^c   Minemoto, M ^b  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Infants; Neonates; Nonlinear mixed effects model; Phenobarbital; Population pharmacokinetics

Indexed keywords

PHENOBARBITAL;

ARTICLE; ASIAN; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODEL; NEWBORN; PERINATAL PERIOD; POPULATION RESEARCH; SEX DIFFERENCE;

ADMINISTRATION, RECTAL; AGING; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CLINICAL TRIALS; FEMALE; HUMANS; INFANT, NEWBORN; JAPAN; MALE; METABOLIC CLEARANCE RATE; PHENOBARBITAL; RETROSPECTIVE STUDIES; SUPPOSITORIES;

EID: 27744468796     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00619.x     Document Type: Article

References (13)

1. Boer HR, Gal P (1982) Neonatal seizures: a survey of current practice. Clinical Pediatrics, 21, 453-457.
2. Wallin A, Jalling B, Boreus LO (1974) Plasma concentrations of phenobarbital in the neonate during prophylaxis for neonatal hyperbilirubinemia. Journal of Pediatrics, 85, 392-397.
3. Beal SL, Sheiner LB (eds) (1992). NONMEM user's guides. San Francisco, CA: NONMEM Project Group, University of California.
4. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503-512.
5. Grasela TH Jr, Donn SM (1985) Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Developmental Pharmacology and Therapeutics, 8, 374-383.
6. Fischer JH, Lockman LA, Zaske D, Kriel R (1981) Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology, 31, 1042-1044.
7. Battino D, Estienne M, Avanzini G (1995) Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clinical Pharmacokinetics, 29, 257-286.
8. Dodson WE, Rust RS Jr (1995) Phenobarbital. Absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th edn. New York: Raven Press, 379-387.
9. Morselli PL (1976) Clinical pharmacokinetics in neonates. Clinical Pharmacokinetics, 1, 81-98.
10. Lockman LA, Kriel R, Zaske D, Thompson T, Virnig N (1979) Phenobarbital dosage for control of neonatal seizures. Neurology, 29, 1445-1449.
11. Pitlick W, Painter M, Pippenger CE (1978) Phenobarbital pharmacokinetics in neonates. Clinical Pharmacology and Therapeutics, 23, 346-350.
12. Jalling B (1975) Plasma concentrations of phenobarbital in the treatment of seizures in newborns. Acta Paediatrica Scandinavica, 64, 514-524.
13. Viswanathan CT, Booker HE, Welling PG (1978) Bioavailability of oral and intramuscular phenobarbital. Journal of Clinical Pharmacology, 18, 100-105.